Articles by Roger Li, MD
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
The panelists share their perspectives on SunRISe-1 and the evolving role of TAR-200 in treating BCG-unresponsive UC.
Treatment Options for BCG-Unresponsive NMIBC: Balancing Efficacy, Logistics, and Patient Preferences
The second segment of this roundtable focuses on the evolving landscape of treatments for BCG-unresponsive bladder cancer.
Part one of this roundtable highlights current practices, emerging therapies, and the future landscape of NMIBC care.
Dr. Li provides background and insights on the implications of his study on oncolytic immunotherapy with nivolumab for MIBC.
Dr. Li describes his post hoc analysis and findings regarding patients with BCG–unresponsive, high-risk NMIBC in ...
Dr. Li details the final results of CORE-001, a phase-2, single arm study of cretostimogene combined with pembrolizumab.
Dr. Li rationalizes the design and potential impact of the MoonRISe-1 study for intermediate-risk NMIBC.
Dr. Li provides commentary on the rationale, design, and impact of the MoonRISe-1 study for intermediate-risk NMIBC.
Dr. Li highlights the EFS data and interesting findings among patients with residual disease in the bladder or lymph nodes.
Dr. Li describes his recent study comparing neoadjuvant pembro vs chemo or upfront cystectomy in patients with MIBC.
Dr. Li details what his study results suggested about ctDNA’s prognostic implications for survival in patients with UTUC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.